Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01805245
Other study ID # 11-0333
Secondary ID
Status Completed
Phase N/A
First received June 15, 2012
Last updated April 17, 2017
Start date January 2012
Est. completion date December 2015

Study information

Verified date April 2017
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the impact of stress reduction on physiological and psychological variables in adults with Type 2 diabetes (T2DM) who have moderate to severe levels of diabetes-related emotional distress. Subjects will be randomized to one of two interventions. We will evaluate the impact of the interventions on glucose metabolism, blood pressure, diabetes-related distress and quality of life. Additionally, we will investigate the role of neuroendocrine dysfunction, systemic inflammation and diabetes self-care practices as mediators in the relationship between increased stress, adverse glucose metabolism and elevated blood pressure in those subjects with T2DM.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date December 2015
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender All
Age group 30 Years and older
Eligibility Inclusion Criteria:

1. Age > 30 years

2. Male or female

3. Duration of diabetes 1-15 years from time of initial diagnosis

4. Diagnosis of T2DM made/confirmed by physician

5. Completed diabetes education in the past

6. Most recent HgA1c >7%; measurement must be within the past 6 months either in physicians office or at the Thriving with Diabetes Boot Camp Class

7. Treatment for diabetes must include any or all of the following modalities:

diet, exercise, oral medications, insulin or other injectable diabetic medication

8. Score > 30 on the Problem Area in Diabetes (PAID) Questionnaire

9. Able to use a glucometer for self-monitoring of blood glucose values

10. Most recent clinic blood pressure less than 180/95

Exclusion Criteria:

1. History of ketoacidosis

2. Age at diagnosis of T2DM < 30 years

3. Score >15 on the PHQ-9

4. Previous training in relaxation or meditation techniques

5. Current practice of yoga, tai chi or any other mind-body movement for > 60 minutes per week

6. Current use of a psychoactive drug for less than 3 months or not yet on a stable dose

7. Inability to participate fully or behave appropriately in the group treatment setting, as observed by baseline acknowledgement of substance abuse, psychotic episode(s), psychiatric hospitalization or history of self- harm within the past 2 years, or current suicidal or homicidal ideation

8. Inability to complete standardized instruments because of a cognitive deficit or language barrier

9. Current use or use within the past 3 months of oral glucocorticoids, excluding intraocular, topical or inhaled preparations

10. History of inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease

11. Use of immune modulating agents

12. Night shift work or other type of schedule in which sleep wake cycle is disrupted

13. Women who consume > 7 alcoholic drinks per week and men who consume > 14 drinks per week

14. Current use or history of daily tobacco use within the past 1 year

15. End stage renal failure on dialysis

16. Pregnancy or post partum <3 months

17. Subjects with known secondary causes of hypertension including renal artery stenosis, pheochromocytoma, coarctation of aorta, hyperaldosteronemia

18. Non-dominant arm circumference > 46cm

19. Unwilling to accept randomization

Study Design


Intervention

Behavioral:
Mindfulness Based Stress Reduction
Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time

Locations

Country Name City State
United States University of North Carolina Chapel Hill North Carolina

Sponsors (1)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Mindfulness To assess mindfulness we will utilize the Five Facet Mindfulness Questionnaire. 0,8,24 weeks
Primary HgA1c We will assess change in glycemic control using the A1c. It will be measured at baseline, immediately following the 8 week intervention and at 24 weeks from baseline. 0,8,24 weeks
Primary Diabetes Distress The Problem Areas in Diabetes will be used to assess the change in diabetes emotional distress at baseline, immediately following the 8 week intervention and at 24 weeks from baseline 0,8,24 weeks
Secondary SF36 Physical Health Score This measure is a patient reported outcome assessing general quality of life and will be assessed using the standardized SF36 tool. 0, 8,24 weeks
Secondary SF36 Mental Health Score This measure is a patient reported outcome assessing general quality of life and will be assessed using the standardized SF36 tool. 0,8,24 weeks
Secondary Mean 24 hour ambulatory systolic blood pressure Mean systolic blood pressure over 24 hours. 0,8,24 weeks
Secondary Mean 24 hour diastolic ambulatory blood pressure Mean diastolic blood pressure over 24 hours 0,8,24 weeks
Secondary HOMA-IR For those participants that are not using insulin, we will assess the degree of insulin resistance using the HOMA-IR, which is derived from the fasting insulin and fasting glucose. 0,8,24 weeks
Secondary Depression Using the Beck Depression Inventory we will assess symptoms of depression using this standardized patient reported outcome. 0,8,24 weeks
Secondary State Anxiety Using the State and Trait Anxiety Assessment we will measure "state" anxiety. 0,8,24 weeks
Secondary Trait Anxiety Using the State and Trait Anxiety Survey we will assess "trait" anxiety. 0,8,24 weeks
Secondary Social Support Using the Duke Social Support and Stress Scale we will assess the degree of social support participants report in their lives. 0,8,24 weeks
Secondary Coping Style Using the Coping Orientation to Problems Experienced Scale, we will evaluate the various coping styles and how they may change over time. 0,8,24 weeks
Secondary General Stress Using the Perceived Stress Scale we will assess general life stressors. 0,8,24 weeks
Secondary Cortisol 24 hour area under the curve Calculating the area under the curve for 24 hours we will assess cortisol secretion as a physiological assessment of stress 0,8,24 weeks
Secondary Cortisol Awakening Response We will measure the cortisol awakening response using measures of cortisol prior to arising and 30 minutes after waking up. 0,8,24 weeks
Secondary IL-6 IL-6 is an assessment of systemic inflammation and will be measured in serum. 0,8, 24 weeks
Secondary Summary of Diabetes Self-Care Activities This patient reported measure assesses the frequency which participants engage in self-care activities that are critical for DM self-management. 0,8,24 weeks
Secondary Average 24 hour glucose by continuous glucose monitor (cgm) Average cgm glucose over 24 hours 0,8,24 weeks
Secondary Average night time glucose Average night time glucose from 10pm-6am using continuous glucose monitoring values 0,8,24 weeks
Secondary Average day time glucose Average day time glucose from 6am-10pm using continuous glucose monitoring values 0,8,24 weeks
Secondary Block Food Frequency Questionnaire Standardized assessment of dietary patterns Week 0
Secondary Mean Day Systolic Ambulatory Blood Pressure The average systolic blood pressure measured by ambulatory blood pressure monitoring between 6 am and 10 pm 0,8,24 weeks
Secondary Mean Day Diastolic Ambulatory Blood Pressure The average systolic blood pressure measured by ambulatory blood pressure monitoring between 6 am and 10 pm 0,8,24 weeks
Secondary Mean Night Systolic Ambulatory Blood Pressure The average systolic blood pressure measured by ambulatory blood pressure monitoring between 10 pm and 6 am. 0,8,24 weeks
Secondary Mean Night Diastolic Ambulatory Blood Pressure The average diastolic blood pressure measured by ambulatory blood pressure monitoring between 10 pm and 6 am. 0,8,24 weeks
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A